导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 64.68% | 31/4773 |
| 近一周 | 1.69% | 263/5465 |
| 近一月 | 0.63% | 494/5421 |
| 近一季 | -16.47% | 4501/5231 |
| 近半年 | 42.69% | 37/4920 |
| 近一年 | 93.70% | 35/4394 |
| 近两年 | 366.78% | 1/2954 |
| 近三年 | 346.19% | 1/2253 |
| 成立以来 | 219.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
11.45% 45/4961 |
88.34% 135/5312 |
- - |
- - |
| 2025 | 109.14% 10/4813 |
-3.67% 3076/3635 |
10.83% 230/4076 |
71.33% 21/4524 |
14.33% 87/4813 |
| 2024 | 29.91% 120/3463 |
3.55% 547/2808 |
2.86% 304/3014 |
13.40% 2175/3129 |
7.56% 441/3463 |
| 2023 | 21.36% 15/2656 |
23.61% 109/2280 |
12.75% 11/2385 |
-10.32% 1984/2515 |
-2.90% 553/2655 |
| 2022 | -27.19% 1461/2207 |
-23.62% 1739/1919 |
6.98% 560/2016 |
-14.97% 1181/2113 |
4.79% 508/2208 |
| 2021 | 13.12% 367/1822 |
-6.51% 1009/1255 |
12.54% 326/1330 |
-7.57% 1063/1466 |
16.33% 52/1822 |
| 2020 | - - |
- - |
17.07% 394/1067 |
-3.62% 1093/1164 |
-1.52% 1109/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 东财通信A VS. 长安沪深300非周期A(740101) |